Patents Assigned to HOCOR Cardiovascular Technologies LLC
-
Patent number: 11826253Abstract: Methods and apparatuses for regulating aortic regurgitation are provided. A catheter shaft is advanced through vasculature so that a flexible occluding membrane coupled to the catheter shaft is positioned within the aorta, typically the ascending aorta above the Sinus of Valsalva and coronary ostia. Blood flow in the aorta causes the flexible occluding membrane to alternate between an expanded occluding configuration while in diastole and a collapsed lesser occluding configuration is systole. The flexible occluding membrane thereby acts as a temporary aortic valve. The flexible occluding membrane is generally conical in shape, with the tip of the cone disposed closer to the aorta than the proximal rim. In diastole, blood flow expands the flexible occluding membrane so that the proximal rim apposes the inner wall of the aorta. The flexible occluding membrane will have one or more openings to allow perfusion of the coronary arteries in diastole.Type: GrantFiled: July 21, 2020Date of Patent: November 28, 2023Assignee: HOCOR CARDIOVASCULAR TECHNOLOGIES LLCInventor: Paul C. Ho
-
Patent number: 11253356Abstract: A delivery system and method for percutaneous aortic valve (PAV) replacement and apparatus used therein. A temporary aortic valve including a reversibly expandable occluder surrounds a central catheter mechanism. The temporary valve is positioned within the ascending aorta, just above and downstream from the coronary ostia. The occluder is configured such that, when fully expanded against the aortic wall, gaps are left that promote continuous coronary perfusion during the cardiac cycle. The temporary valve substitutes for the function of the native aortic valve during its replacement. The native aortic valve is next dilated, and then ablated through deployment of low profile, elongated, sequentially delivered stents. The stent(s) displace the native tissues and remain within the aortic annulus to receive and provide a structure for retaining the PAV. The PAV is delivered, positioned and deployed within the stent(s) at the aortic annulus with precision and relative ease.Type: GrantFiled: August 17, 2018Date of Patent: February 22, 2022Assignee: HOCOR CARDIOVASCULAR TECHNOLOGIES, LLCInventor: Paul C. Ho
-
Patent number: 10881412Abstract: Methods and systems for regulating aortic regurgitation during aortic valve replacement or repair procedures utilize a temporary aortic valve (TAV) catheter and a controller. The temporary aortic valve catheter has an expandable occlusion device which can partially occlude the aortic lumen during ventricular diastole with a lesser occlusion during ventricular systole. Exemplary balloon structures include multiple, independently inflatable balloons which are inflated in synchrony with the cardiac cycle by the controller. By controlling aortic regurgitation, the repair or replacement protocols can be conducted with less interference from blood flow.Type: GrantFiled: September 12, 2018Date of Patent: January 5, 2021Assignee: HOCOR Cardiovascular Technologies, LLCInventor: Paul C. Ho
-
Patent number: 10751181Abstract: Methods and apparatuses for regulating aortic regurgitation are provided. A catheter shaft is advanced through vasculature so that a flexible occluding membrane coupled to the catheter shaft is positioned within the aorta, typically the ascending aorta above the Sinus of Valsalva and coronary ostia. Blood flow in the aorta causes the flexible occluding membrane to alternate between an expanded occluding configuration while in diastole and a collapsed lesser occluding configuration is systole. The flexible occluding membrane thereby acts as a temporary aortic valve. The flexible occluding membrane is generally conical in shape, with the tip of the cone disposed closer to the aorta than the proximal rim. In diastole, blood flow expands the flexible occluding membrane so that the proximal rim apposes the inner wall of the aorta. The flexible occluding membrane will have one or more openings to allow perfusion of the coronary arteries in diastole.Type: GrantFiled: November 22, 2017Date of Patent: August 25, 2020Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Patent number: 10098644Abstract: Methods and systems for regulating aortic regurgitation during aortic valve replacement or repair procedures utilize a temporary aortic valve (TAV) catheter and a controller. The temporary aortic valve catheter has an expandable occlusion device which can partially occlude the aortic lumen during ventricular diastole with a lesser occlusion during ventricular systole. Exemplary balloon structures include multiple, independently inflatable balloons which are inflated in synchrony with the cardiac cycle by the controller. By controlling aortic regurgitation, the repair or replacement protocols can be conducted with less interference from blood flow.Type: GrantFiled: March 2, 2016Date of Patent: October 16, 2018Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Patent number: 10080654Abstract: A delivery system and method for percutaneous aortic valve (PAV) replacement and apparatus used therein. A temporary aortic valve including a reversibly expandable occluding medium surrounds a central catheter mechanism. The temporary valve is positioned within the ascending aorta, just above and downstream from the coronary ostia. The occluding medium is configured such that, when fully expanded against the aortic wall, gaps are left that promote continuous coronary perfusion during the cardiac cycle. The temporary valve substitutes for the function of the native aortic valve during its replacement. The native aortic valve is next dilated, and then ablated through deployment of low profile, elongated, sequentially delivered stents. The stent(s) displace the native tissues and remain within the aortic annulus to receive and provide a structure for retaining the PAV. The PAV is delivered, positioned and deployed within the stent(s) at the aortic annulus with precision and relative ease.Type: GrantFiled: September 27, 2016Date of Patent: September 25, 2018Assignee: HOCOR Cardiovascular Technologies, LLCInventor: Paul C. Ho
-
Patent number: 9855143Abstract: Methods and apparatuses for regulating aortic regurgitation are provided. A catheter shaft is advanced through vasculature so that a flexible occluding membrane coupled to the catheter shaft is positioned within the aorta, typically the ascending aorta above the Sinus of Valsalva and coronary ostia. Blood flow in the aorta causes the flexible occluding membrane to alternate between an expanded occluding configuration while in diastole and a collapsed lesser occluding configuration is systole. There flexible occluding membrane thereby acts as a temporary aortic valve. The flexible occluding membrane is generally conical in shape, with the tip of the cone disposed closer to the aorta than the proximal rim. In diastole, blood flow expands the flexible occluding membrane so that the proximal rim apposes the inner wall of the aorta. The flexible occluding membrane will have one or more openings to allow perfusion of the coronary arteries in diastole.Type: GrantFiled: March 29, 2016Date of Patent: January 2, 2018Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Patent number: 9700410Abstract: A catheter adapted for placement in the ascending aorta comprises a central catheter mechanism and a balloon structure or other occluding structure at its distal end. The catheter may be placed over the aortic arch such that the occluding structure is placed in the ascending aorta just above the Sinus of Valsalva and coronary ostia. Once in place, the occluding structure is inflated to control blood flow through the aorta during aortic valve ablation and replacement protocols.Type: GrantFiled: January 14, 2014Date of Patent: July 11, 2017Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Patent number: 9480564Abstract: A delivery system and method for percutaneous aortic valve (PAV) replacement and apparatus used therein. A temporary aortic valve including a reversibly expandable occluder surrounds a central catheter mechanism. The temporary valve is positioned within the ascending aorta, just above and downstream from the coronary ostia. The occluder is configured such that, when fully expanded against the aortic wall, gaps are left that promote continuous coronary perfusion during the cardiac cycle. The temporary valve substitutes for the function of the native aortic valve during its replacement. The native aortic valve is next dilated, and then ablated through deployment of low profile, elongated, sequentially delivered stents. The stent(s) displace the native tissues and remain within the aortic annulus to receive and provide a structure for retaining the PAV. The PAV is delivered, positioned and deployed within the stent(s) at the aortic annulus with precision and relative ease.Type: GrantFiled: January 14, 2014Date of Patent: November 1, 2016Assignee: HOCOR Cardiovascular Technologies, LLCInventor: Paul C. Ho
-
Patent number: 9308086Abstract: Methods and systems for regulating aortic regurgitation during aortic valve replacement or repair procedures utilize a temporary aortic valve (TAV) catheter and a controller. The temporary aortic valve catheter has an expandable occlusion device which can partially occlude the aortic lumen during ventricular diastole with a lesser occlusion during ventricular systole. Exemplary balloon structures include multiple, independently inflatable balloons which are inflated in synchrony with the cardiac cycle by the controller. By controlling aortic regurgitation, the repair or replacement protocols can be conducted with less interference from blood flow.Type: GrantFiled: September 7, 2011Date of Patent: April 12, 2016Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Publication number: 20140200658Abstract: A catheter adapted for placement in the ascending aorta comprises a central catheter mechanism and a balloon structure or other occluding structure at its distal end. The catheter may be placed over the aortic arch such that the occluding structure is placed in the ascending aorta just above the Sinus of Valsalva and coronary ostia. Once in place, the occluding structure is inflated to control blood flow through the aorta during aortic valve ablation and replacement protocols.Type: ApplicationFiled: January 14, 2014Publication date: July 17, 2014Applicant: HOCOR Cardiovascular Technologies LLCInventor: Paul C. HO
-
Publication number: 20140142692Abstract: A delivery system and method for percutaneous aortic valve (PAV) replacement and apparatus used therein. A temporary aortic valve including a reversibly expandable occluding means surrounds a central catheter mechanism. The temporary valve is positioned within the ascending aorta, just above and downstream from the coronary ostia. The occluding means is configured such that, when fully expanded against the aortic wall, gaps are left that promote continuous coronary perfusion during the cardiac cycle. The temporary valve substitutes for the function of the native aortic valve during its replacement. The native aortic valve is next dilated, and then ablated through deployment of low profile, elongated, sequentially delivered stents. The stent(s) displace the native tissues and remain within the aortic annulus to receive and provide a structure for retaining the PAV. The PAV is delivered, positioned and deployed within the stent(s) at the aortic annulus with precision and relative ease.Type: ApplicationFiled: January 14, 2014Publication date: May 22, 2014Applicant: HOCOR Cardiovascular Technologies LLCInventor: Paul C. HO
-
Patent number: 8663319Abstract: A delivery system and method for percutaneous aortic valve (PAV) replacement and apparatus used therein. A temporary aortic valve including a reversibly expandable occluding means surrounds a central catheter mechanism. The temporary valve is positioned within the ascending aorta, just above and downstream from the coronary ostia. The occluding means is configured such that, when fully expanded against the aortic wall, gaps are left that promote continuous coronary perfusion during the cardiac cycle. The temporary valve substitutes for the function of the native aortic valve during its replacement. The native aortic valve is next dilated, and then ablated through deployment of low profile, elongated, sequentially delivered stents. The stent(s) displace the native tissues and remain within the aortic annulus to receive and provide a structure for retaining the PAV. The PAV is delivered, positioned and deployed within the stent(s) at the aortic annulus with precision and relative ease.Type: GrantFiled: July 25, 2008Date of Patent: March 4, 2014Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Patent number: 8663318Abstract: A catheter adapted for placement in the ascending aorta comprises a central catheter mechanism and a balloon structure or other occluding structure at its distal end. The catheter may be placed over the aortic arch such that the balloon structure is placed in the ascending aorta just above the Sinus of Valsalva and coronary ostia. Once in place, the balloon structure is inflated to control blood flow through the aorta during aortic valve ablation and replacement protocols.Type: GrantFiled: July 23, 2007Date of Patent: March 4, 2014Assignee: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho
-
Publication number: 20120116439Abstract: Methods and systems for regulating aortic regurgitation during aortic valve replacement or repair procedures utilize a temporary aortic valve (TAV) catheter and a controller. The temporary aortic valve catheter has an expandable occlusion device which can partially occlude the aortic lumen during ventricular diastole with a lesser occlusion during ventricular systole. Exemplary balloon structures include multiple, independently inflatable balloons which are inflated in synchrony with the cardiac cycle by the controller. By controlling aortic regurgitation, the repair or replacement protocols can be conducted with less interference from blood flow.Type: ApplicationFiled: September 7, 2011Publication date: May 10, 2012Applicant: HOCOR Cardiovascular Technologies LLCInventor: Paul C. Ho